Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Invivyd appointed Chairman Marc Elia as Chief Executive Officer, adding the top executive role to his existing responsibilities while Ajay Royan was named Lead Independent Director. Ian Sheffield also joined the board as an independent director, bringing two decades of healthcare investment experience. The company provided a regulatory update for its VYD2311 program, anticipating top-line data from the Phase 3 DECLARATION and LIBERTY studies by the end of Q3 2026. Management plans to unblind the DECLARATION study and submit a Biologics License Application, pursuing either traditional or accelerated approval paths.
Key figures
- Drug Name
- VYD2311
- Phase Of Trial
- Phase 3
- Liberty enrollment
- approximately 210
- Data readout timing
- end of Q3 2026
- Declaration enrollment
- approximately 2,400
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.